Rita A. Karachun - 05 Jun 2026 Form 4 Insider Report for Coherus Oncology, Inc. (CHRS)

Reporting relationship: Director
Issuer ticker: CHRS
Reported as of: 05 Jun 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 09 Jun 2026, 18:43:22 UTC
Prior SEC filing: 13 Jun 2025
Source filing: View source filing
Reporting owner signature: /s/ Bryan McMichael, as Attorney-in-Fact for Rita A. Karachun

Key filing fact

Rita A. Karachun filed Form 4 for Coherus Oncology, Inc. (CHRS) on 09 Jun 2026.

Key facts

This page summarizes Rita A. Karachun's Form 4 filing for Coherus Oncology, Inc. (CHRS).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 09 Jun 2026, 18:43.

Change

Previous filing in this sequence was filed on 13 Jun 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001601572 Primary reporting owner

Karachun Rita A

Relationship: Director
Address: C/O COHERUS ONCOLOGY, INC., 333 TWIN DOLPHIN DRIVE, SUITE 600, REDWOOD CITY
Signature: /s/ Bryan McMichael, as Attorney-in-Fact for Rita A. Karachun
Signature date: 09 Jun 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CHRS transaction

Common Stock

Award

Transaction value
Shares: +30,000
Change %
Price: $0.000000^*
Shares after: 30,000
Date: 05 Jun 2026
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CHRS transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares: +60,000
Change %
Price: $0.000000^*
Shares after: 60,000
Date: 05 Jun 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 60,000
Exercise price: $1.45
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 100% of the RSUs shall vest on the one year anniversary of June 3, 2026, subject to Reporting Person's continued service relationship with the Issuer on such vesting date.

Footnote F2

The underlying shares vest and become exercisable as to 100% of the total number of the shares subject to the option on June 3, 2027, subject to the Reporting Person's continued service relationship with the Issuer on such vesting date.